mercilon tafla 150 míkróg/20 míkróg
n.v. organon* - desogestrelum inn; ethinylestradiolum inn - tafla - 150 míkróg/20 míkróg
vidisic augnhlaup 2 mg/g
gerhard mann dr., chem.-pharm. fabrik gmbh - carbomerum inn - augnhlaup - 2 mg/g
hyprosan (hypromellose) augndropar, lausn 3,2 mg/ml
santen oy - hypromellosum inn - augndropar, lausn - 3,2 mg/ml
oftagel augnhlaup 2,5 mg/g
santen oy* - carbomer - augnhlaup - 2,5 mg/g
oftagel augnhlaup í stakskammtaíláti 2,5 mg/g
santen oy* - carbomer - augnhlaup í stakskammtaíláti - 2,5 mg/g
oculac augndropar, lausn 5 %
alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %
oculac án rotvarnar augndropar, lausn 5 %
alcon nordic a/s - povidonum k25 - augndropar, lausn - 5 %
bleomycin baxter stungulyfs-/innrennslisstofn, lausn 15.000 a.e.
baxter medical ab* - bleomycinum súlfat - stungulyfs-/innrennslisstofn, lausn - 15.000 a.e.
ikervis
santen oy - ciclosporin - kviðsjúkdómar - augnlækningar - meðferð við alvarlegum glærubólgu hjá fullorðnum sjúklingum með þurr auganu, sem hefur ekki batnað þrátt fyrir meðferð með tárubólgu.
blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - mergæxli - Æxlishemjandi lyf - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.